India pushes for quicker US FDA inspections

The Indian government has urged the United States to enhance the frequency of inspections carried out by the US Food and Drug Administration (FDA) in India, aiming to boost pharmaceutical exports.

Both nations engaged in discussions at a meeting, addressed concerns about overreliance and insufficient diversity in Active Pharmaceutical Ingredients (APIs) within the global pharmaceutical supply chain.

Noting that the pandemic led to a significant backlog of US FDA inspections of Indian facilities, Minister Piyush Goyal said the delay has disrupted production and slowed down approvals. He said faster inspections will lead to quicker approvals for Indian drugs in the US market, a major destination for Indian pharmaceuticals.